Phase I Single Dose Safety and Pharmacokinetic Study of Bowman Birk Inhibitor Concentrate, Delivered as an Orange Juice Suspension to Healthy Male Volunteers Between 18 and 65 Years of Age.
Latest Information Update: 31 Mar 2023
At a glance
- Drugs Bowman-Birk inhibitor concentrate (Primary)
- Indications Cancer
- Focus Adverse reactions
- 28 Aug 2007 Status change from recruiting to completed.
- 11 Sep 2006 New trial record.